Important note

This AI stock analysis for Regeneron is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

Regeneron - AI Stock Analysis

Analysis generated December 6, 2024

Regeneron Pharmaceuticals is a biotechnology company that focuses on discovering, developing, manufacturing, and commercializing medicines for the treatment of serious medical conditions. With a strong pipeline and a reputation for innovation, Regeneron has established itself as a leader in the biotech industry. However, recent data presents a mixed picture, necessitating a deeper analysis of its financials, stock performance, and market sentiment.

Fundamental Analysis

Revenue for the last quarter was $3.72 billion. This is an increase of 4.89% compared to the quarter before, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of 11.24%, suggesting positive year-over-year growth. This indicates that Regeneron continues to expand its business and generate higher sales.

Net income for the last quarter was $1.34 billion. This represents a decrease of 6.40% compared to the quarter before, indicating a need for concern. However, compared to the same quarter last year, there is an increase of 33.02%, suggesting positive year-over-year growth. The fluctuation in net income might hint at operational inefficiencies or increased costs that need addressing.

EBITDA for the last quarter was $0, representing a decrease of 100.00% compared to the quarter before. The same 100.00% decrease is also recorded compared to the same quarter last year. This is a severe concern, indicating that Regeneron's operations are not generating cash flow, which is critical for sustaining business activities and growth.

The current Price-to-Earnings (P/E) ratio is 18.55, which appears within a normal range, neither particularly high nor low. This suggests that the stock is fairly valued based on its earnings. However, it is essential to keep in mind other metrics and market conditions.

Additionally, recent insider selling could be interpreted as a bearish signal. If company insiders are offloading their stocks, it could imply that they foresee potential issues or a downside in the stock’s future performance.

Technical Analysis

Today's stock price is $775.46. This represents a decrease of 5.04% compared to a month ago, which may be concerning in the short term. Furthermore, compared to a year ago, there is a decrease of 8.68%, which could be a cause for long-term concern. However, the trend is bullish, which indicates potential upside in the future.

The current Simple Moving Average (SMA10) is $756.97, marginally higher than the previous SMA10 of $754.73. This suggests a potential upward trend in price movement. The Relative Strength Index (RSI) is 45.4, indicating a neutral condition—not too overbought or oversold, which implies minimal immediate buying or selling pressure.

Alternative Data Analysis

Focusing on job postings and employee sentiment, Regeneron currently has 394 open positions. This number is down by 16% in the last couple of months, indicating a company attempting to improve its margins or cut costs, not a great sign for a growing company. The business outlook among employees at Regeneron is neutral, suggesting neither strong nor weak internal sentiment.

Customer acquisition trends reveal that Regeneron has an estimated 420,000 visitors to their webpage. The number of visitors is up by 54% in the last couple of months, which is a bullish trend, as it may indicate an increase in potential customers.

Customer engagement data shows that Regeneron has 14,000 followers on their Instagram page, with an increase of 4% in the last couple of months, indicating growing interest. On Twitter, Regeneron has 33,000 followers, although this number is down by 1% recently, which might indicate a slight decrease in interest.

Finally, the AltIndex’s AI score for Regeneron is 54, signaling a 'hold'. This suggests that based on fundamental, technical, and alternative data analysis, the stock is expected to maintain its current price levels in the short term.

Conclusion

In conclusion, Regeneron presents a mixed bag of both encouraging and cautionary signs. While revenues and net income see robust year-over-year growth, significant concern lies in the declining net income quarter-over-quarter and the alarming zero EBITDA. The technical analysis offers some hope with an upward trend, but recent short-term losses and insider selling may instill a need for caution. Alternative data points such as web traffic and social media engagement show a mixed but generally positive sentiment. Given these varied signals and the AI score of 54, a 'hold' recommendation seems prudent. Investors should closely monitor future earnings reports and other significant company updates.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.